For Patient
Delivering Affordable Innovation to Patients
Clinical
Trial
HELP Cardio-X
Program
iPSC Bank
for ALS
Clinical Trial
Adhering to the core values of "Customer-centered Care," we are committed to providing safe, effective, and affordable cell therapy for all patients with degenerative diseases. We focus not only on cell product innovation but also on improving accessibility and affordability for patients. We place a high priority on communication with customers throughout the development of cell products.
Treating Heart Failure With hPSC-CMs (HEAL-CHF)
In 2021, Help Therapeutics achieved the first clinical approval (MR-32-21-014649) of iPSC-based cell therapy filed by the National Health Commission of China. We cooperate with Nanjing Drum Tower Hospital to treat heart failure using our iPSC-derived cardiomyocytes.
To learn more about our clinical trial, please check ChinicalTrials.gov.
To learn more about our clinical trial, please check ChinicalTrials.gov.
HELP Cardio-X Program
Human iPSC Preservation issued by the Ministry of Science and Technology of the People's Republic of China ([2021] BC0022)
Background
Smoking, obesity, hypertension, hyperlipemia, and hyperglycemia are recognized as high-risk factors for cardiovascular disease. Coronary artery atherosclerosis leads to narrowing of blood vessels and insufficient blood supply to the heart muscle, resulting in coronary heart disease.
In myocardial infarction, a portion of the coronary artery is completely blocked, resulting in myocardial necrosis.
Long-term ischemia of the heart muscle causes extensive necrosis, and the heart gradually becomes fibrotic and cannot contract normally, leading to heart failure.
In myocardial infarction, a portion of the coronary artery is completely blocked, resulting in myocardial necrosis.
Long-term ischemia of the heart muscle causes extensive necrosis, and the heart gradually becomes fibrotic and cannot contract normally, leading to heart failure.
Process
Autologous iPSC preservation is the first step of individualized treatment in the future.
Only 8-16 ml of peripheral blood needs to be collected, then iPSC can be produced by Help Cell-foundry platform. The seed iPSC could be preserved in CBiPS or a cell bank built with a partner hospital.
Step 1
Collect 8-16 ml peripheral blood
Step 2
Isolate Peripheral blood mononuclear cells (PBMC) from peripheral blood
Step 3
Reprogram PBMC to iPSC and store it
Step 4
Differentiate iPSC into cardiomyocytes
Step 5
Transplantation of cardiomyocytes can be done after clinical evaluation
Suggestion
According to Nature Biotechnology, the donor's age is related to the safety of iPSCs. The older the donor is, the higher risk of mutants on epigenetics and genetics. We recommend preparing and storing iPSC at a young age.
iPSC Bank for ALS
Introduction
Help Therapeutics provides free iPSC reprogramming technical support to establish "iPSC Bank for ALS." We adhere to the principle of "use-oriented, open sharing" for helping Amyotrophic lateral sclerosis (ALS) patients.
Core Contents
Sample collection & preservation
In the project's first step, Help Therapeutics calls on ALS patients for iPSC preparation and preserves samples in a hospital-co-constructed cell bank.
Mapping "human- ALS multi-omics profiles"
Help Therapeutics cooperates with scientists to integrate multidimensional data like single-cell sequencing, chromatin accessibility, and spatial transcriptome analysis to discover the pathology and targets of ALS and explore therapies for this disease.
Translation: To promote ALS drug development
We call on domestic pharmaceutical companies to participate in therapeutic development to treat ALS, and our iPSC disease model will be provided to companies that are developing or will develop ALS pipelines. Companies can submit an application to CBiPS and receive a human-derived disease model upon approval.